(NASDAQ: RGNX) Regenxbio's forecast annual revenue growth rate of 49.81% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Regenxbio's revenue in 2025 is $83,328,000.On average, 6 Wall Street analysts forecast RGNX's revenue for 2025 to be $14,783,875,267, with the lowest RGNX revenue forecast at $4,006,891,040, and the highest RGNX revenue forecast at $22,696,984,210. On average, 5 Wall Street analysts forecast RGNX's revenue for 2026 to be $13,345,150,953, with the lowest RGNX revenue forecast at $4,023,920,327, and the highest RGNX revenue forecast at $22,889,365,066.
In 2027, RGNX is forecast to generate $14,583,580,801 in revenue, with the lowest revenue forecast at $10,944,822,876 and the highest revenue forecast at $17,520,131,072.